Tag: pharmaceutical

Drugmakers run the largest direct-to-consumer advertising category in the United States. New 5W research finds AI citation share does not follow the ad budget...

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of June 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

SAN DIEGO and SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's...

FLORHAM PARK, N.J., June 19, 2026 (GLOBE NEWSWIRE) -- Exeltis USA, Inc. (Exeltis), a global pharmaceutical company specializing in women’s health, announced that the U.S. Food and Drug Administration (FDA) has approved an update to the labeled strength of TWIRLA® (levonorgestrel and ethinyl estradiol) transdermal system. The new labeled strength will begin to appear on the market in September or October of 2026.

Lite Strategy to Attend Panel at Litecoin Foundation Summit in Amsterdam

Microsoft (MSFT) Faces Securities Fraud Class Action after Copilot Issues Cause 10% Stock Drop – Investors Notified to Contact BFA Law

Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

DELRAY BEACH, Fla., June 19, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the gelatin market is estimated at USD 4.59 billion in 2026 and is...

TOKYO, June 19, 2026 /PRNewswire/ -- The NX Group, comprising companies under NIPPON EXPRESS HOLDINGS, Inc., will participate in "Multimodal 2026" to be held...

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery for cardiometabolic diseases (CMDs).

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website.

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

DRAPER, Utah, June 18, 2026 /PRNewswire/ -- CenExel, a leading, wholly owned clinical research site network, announced today the expansion of its leadership team...

KRTL announces RAYEL and PERIKO, a coca-derived beverage and pharmaceutical development platform supported by KRTL subsidiaries and CIQ.